<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Eur Neuropsychopharmacol</journal-id><journal-title-group><journal-title>European Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0924-977X</issn><issn pub-type="epub">1873-7862</issn><publisher><publisher-name>Elsevier B.V. and ECNP.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">S0924-977X(20)30093-6</article-id><article-id pub-id-type="doi">10.1016/j.euroneuro.2020.03.018</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Challenges of methadone maintenance treatment during the COVID-19 epidemic in China: Policy and service recommendations</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0001"><name><surname>Jiang</surname><given-names>Haifeng</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0002"><name><surname>Su</surname><given-names>Hang</given-names></name><xref rid="aff0001" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0003"><name><surname>Zhang</surname><given-names>Changchun</given-names></name><xref rid="aff0003" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0004"><name><surname>Liu</surname><given-names>Xuebing</given-names></name><xref rid="aff0004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0005"><name><surname>Li</surname><given-names>Ruihua</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0006"><name><surname>Zhong</surname><given-names>Na</given-names></name><xref rid="aff0001" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0007"><name><surname>Zhao</surname><given-names>Min</given-names></name><email>drminzhao@smhc.org.cn</email><xref rid="aff0001" ref-type="aff">a</xref><xref rid="aff0002" ref-type="aff">b</xref><xref rid="aff0005" ref-type="aff">e</xref><xref rid="aff0006" ref-type="aff">f</xref><xref rid="cor0001" ref-type="corresp">&#x0204e;</xref></contrib><aff id="aff0001"><label>a</label>Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China</aff><aff id="aff0002"><label>b</label>Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China</aff><aff id="aff0003"><label>c</label>Wuhan Sixth Hospital Affiliated to Jianghan University, Wuhan, China</aff><aff id="aff0004"><label>d</label>Wuhan Mental Health Center, Wuhan, China</aff><aff id="aff0005"><label>e</label>CAS Center for Excellence in Brain Science and Intelligence Technology (CEBSIT), Chinese Academy of Sciences, Shanghai, China</aff><aff id="aff0006"><label>f</label>Institute of Psychological and Behavioral Science, Shanghai Jiao Tong University, Shanghai, China</aff></contrib-group><author-notes><corresp id="cor0001"><label>&#x0204e;</label>Corresponding author at: Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China. <email>drminzhao@smhc.org.cn</email></corresp><fn id="fn1"><label>1</label><p id="notep0001">Haifeng Jiang, Hang Su and Changchun Zhang contributed equally.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>13</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>13</day><month>4</month><year>2020</year></pub-date><volume>35</volume><fpage>136</fpage><lpage>137</lpage><history><date date-type="received"><day>17</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Elsevier B.V. and ECNP. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><p id="para0002">The methadone maintenance treatment (MMT) program, implemented by the Chinese government to control illegal drug abuse, has been operating as a nation-wide program since its initiation in 2004 (<xref rid="bib0005" ref-type="bibr">Sullivan&#x000a0;et&#x000a0;al., 2015</xref>). By the end of 2017, it has established an extensive network of 789 community MMT clinics in 29 provinces, with 162,000 patients receiving treatments everyday (<xref rid="bib0001" ref-type="bibr">Committee,&#x000a0;2019</xref>). According to the regulation, patients registered with the MMT program are required to visit a designated clinic daily to take medication.</p><p id="para0003">Since the novel coronavirus disease 2019 (COVID-19) epidemic, the local government of Wuhan has implemented measures to control the epidemic, including restricting population mobility through traffic control, etc. However, these measures make it difficult for MMT patients to go to the clinics. Furthermore, some patients were afraid of walking to the clinics because it may increase the risk of contracting virus in public. If the patient is offered to take methadone home without a comprehensive monitoring plan, it may cause serious consequences such as overdose and illegal drug trade.</p><p id="para0004">Take the Liu Jiao Ting MMT clinic as an example, the clinic is located in central area of the COVID-19 epidemic (close to the Hua Nan Seafood Market) in Wuhan, serving 300 MMT patients living in the surrounding communities. The average number of visits decreased from 127 persons per day to 109 persons per day. We just finished a small survey using PHQ-9 and GAD-7 for 17 clients. Participants experienced some level of depression (PHQ mean score 14.65&#x000b1;5.37) and anxiety (GAD mean score 11.65&#x000b1;4.14). 14 participants reported it was difficulty to go to the clinic for medication, and 2 participants reported having been exposed to COVID-19 patients, while luckily no patients have been infected so far. The situation of the other 11 MMT clinics in Wuhan is very similar to that in Liu Jiao Ting clinic.</p><p id="para0005">Concerning the epidemic and special situation of MMT clinics in China, timely special management measures for maintaining and improving services for substance-dependent patients should be developed urgently. We propose the following recommendation: (1) the national public health emergency system should pay attention to MMT patients and other substance-dependent populations, including medication delivery, each prescription dosage and related regulations. (2) communications between the clinic and patients and between clinics should be strengthened via a variety of channels such as phone, mobile app (e.g. WeChat), or social media sites (<xref rid="bib0002" ref-type="bibr">Liu&#x000a0;et&#x000a0;al., 2020</xref>). (3) In order to prevent the client from COVID-19 infection, clinics in epidemic areas could carry out &#x0201c;Take-home dosing plan&#x0201d; based on special provisions for high- and low-risk patients and patients with disabilities (<xref rid="bib0003" ref-type="bibr">Matusow&#x000a0;et&#x000a0;al., 2018</xref>). Patients, whose daily dose is low, who usually have good compliance records, and who have no illegal records, could be allowed to take home a dose of 3 to 5 days. Implementing online appointments to get methadone with a propose dose is also necessary to reduce the risk of cross-contact of patients when visiting the clinic (<xref rid="bib0004" ref-type="bibr">Qiu&#x000a0;et&#x000a0;al., 2020</xref>).</p><sec id="sec0024a"><title>Conflict of Interest</title><p id="para0079">We declared no conflict of interests.</p></sec></body><back><ref-list id="cebibl1"><title>References</title><ref id="bib0001"><mixed-citation publication-type="other" id="othref0001">China National Narcotic Control Committee, 2019. China Drug Report (2018).</mixed-citation></ref><ref id="bib0002"><element-citation publication-type="journal" id="sbref0001"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Xiang</surname><given-names>Y.-.T.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>Online mental health services in China during the COVID-19 outbreak</article-title><source>Lancet Psychiatry</source><year>2020</year></element-citation></ref><ref id="bib0003"><element-citation publication-type="journal" id="sbref0002"><person-group person-group-type="author"><name><surname>Matusow</surname><given-names>H.</given-names></name><name><surname>Benoit</surname><given-names>E.</given-names></name><name><surname>Elliott</surname><given-names>L.</given-names></name><name><surname>Dunlap</surname><given-names>E.</given-names></name><name><surname>Rosenblum</surname><given-names>A.</given-names></name></person-group><article-title>Challenges to opioid treatment programs after hurricane sandy: patient and provider perspectives on preparation, impact, and recovery</article-title><source>Subst. Use Misuse</source><volume>53</volume><year>2018</year><fpage>206</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">28296524</pub-id></element-citation></ref><ref id="bib0004"><element-citation publication-type="journal" id="sbref0003"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Xie</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations</article-title><source>General Psychiatry</source><volume>33</volume><year>2020</year><object-id pub-id-type="publisher-id">e100213</object-id></element-citation></ref><ref id="bib0005"><element-citation publication-type="journal" id="sbref0004"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>S.G.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Rou</surname><given-names>K.</given-names></name><name><surname>Pang</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>E.</given-names></name><name><surname>Mi</surname><given-names>G.</given-names></name></person-group><article-title>Who uses methadone services in China? Monitoring the world's largest methadone programme</article-title><source>Addiction</source><volume>110</volume><year>2015</year><fpage>29</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">25533862</pub-id></element-citation></ref></ref-list></back></article>